Dr. Bombardier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from AstraZeneca, Pfizer, Biogen Idec, PESI Healthcare, and Roche, and (more than $10,000 each) from Abbott Canada and Abbott International, Wyeth (Merck), and Schering (Merck).
Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review
Article first published online: 28 DEC 2010
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 1, pages 65–78, January 2011
How to Cite
van der Velde, G., Pham, B., Machado, M., Ieraci, L., Witteman, W., Bombardier, C. and Krahn, M. (2011), Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review. Arthritis Care Res, 63: 65–78. doi: 10.1002/acr.20338
- Issue published online: 28 DEC 2010
- Article first published online: 28 DEC 2010
- Accepted manuscript online: 25 AUG 2010 03:01PM EST
- Manuscript Accepted: 19 AUG 2010
- Manuscript Received: 29 JAN 2010
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.